BFNH / BioForce Nanosciences Holdings, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) O

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SEC

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

(Check One): [ X ] Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) O

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SEC

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) O

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (S

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1 to Form 10-Q) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITIO

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No.1 to Form 10-Q) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exac

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2021 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation

Merle Ferguson 2020 General Booth Blvd., Suite 230 Virginia Beach, Virginia 23454

EX-17.1 2 ex171.htm RESIGNATION LETTER Merle Ferguson 2020 General Booth Blvd., Suite 230 Virginia Beach, Virginia 23454 November 29, 2021 Board of Directors BioForce Nanoscience, Inc. 2020 General Booth Blvd., Suite 253 Virginia Beach, Virginia 23454 Dear Board of Directors, I, Merle Ferguson, on the close of business, Monday, November 29, 2021, hereby resign as BioForce Nanosciences Holdings, In

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐  TRANSITION REPORT UNDER SECTION 13 OR 1

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074   BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) ☒  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ☐  TRANSITION

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) ? ?QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ? ?TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 ? BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exa

CONSULTING AGREEMENT

Exhibit 10.1 CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on April 16, 2021, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE OF SERVICES. The manner in which the S

CONSULTING AGREEMENT

Exhibit 10.1 CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on April 16, 2021, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE OF SERVICES. The manner in which the S

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. [ ]  TRANSITION REPORT UNDER SECTION 13 OR 1

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] ?QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. [ ] ?TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 ? BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 02, 2021 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Co

Quarterly Report - QTR. REPORT -MARCH 31, 2021

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifi

Annual Report - YEAR END REPORT DEC. 31, 2020

10-K 1 bfnh01222021form10kdec2020.htm YEAR END REPORT DEC. 31, 2020 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS

- CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 4, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 85-2138858 (State or other jurisdiction of incorporation)

Quarterly Report - QTR. REPORT - SEPT. 30, 2020

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spe

- CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 09, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)

MEMORANDUM OF UNDERSTANDING

Converted by EDGARwiz Exhibit 10.8 MEMORANDUM OF UNDERSTANDING This Memorandum of Understanding (“MOU”), dated July 14, 2020 is by and between BioForce Nanosciences Holdings, Inc. (“BFNH”), a Nevada Corporation and Element Global, Inc., a Utah Corporation (ELGL) (BFNH and ELGL may individually referred to hereinafter as “Party” collectively referred to hereinafter as the “Parties”). This MOU sets

RSDL ENTERPRISES CONSULTING AGREEMENT

Exhibit 10.7 RSDL ENTERPRISES CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia of RSDL Enterprises. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on May 25, 2020, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE OF

Quarterly Report - QTR. REPORT - JUNE 30, 2020

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 14, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Co

Other Events

8-K/A 1 bfnh07092020form8ka.htm AMENDED: CHANGED WORD "FORMERLY" WITH "FORMALLY" UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No.1 to Form 8-K) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registr

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Com

Current Report

8-K 1 bfnh05182020form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State

Quarterly Report - QTR. REPORT -MARCH 31, 2020

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie

SUBSCRIPTION AGREEMENT

Exhibit #10.5 SUBSCRIPTION AGREEMENT TO: The Board of Directors BioForce Nanosciences Holdings, Inc. 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 23454 Dear Director: The undersigned, Richard Kaiser, hereby subscribes to 500,000 shares of the $0.0001 par value Preferred Series ‘A’ stock (the "Shares") of BioForce Nanosciences Holdings, Inc. (BFNH) a corporation duly organized under the la

Employment Agreement – Merle Ferguson (1)

Exhibit 10.1 Chairman of the Board/ President/CEO Compensation AGREEMENT This Chairman and President Compensation Agreement (this “Agreement”) is made as of the 31st day of March, 2020 by and among Bioforce Nanosciences Holdings, Inc. (BFNH) a Nevada Corporation, having its principal place of business at 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 23454 (“Company”), and Merle Ferguson, C

SUBSCRIPTION AGREEMENT

Exhibit #10.4 SUBSCRIPTION AGREEMENT TO: The Board of Directors BioForce Nanosciences Holdings, Inc. 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 23454 Dear Director: The undersigned, Merle Ferguson, hereby subscribes to 1,500,000 shares of the $0.0001 par value Preferred Series ‘A’ stock (the "Shares") of BioForce Nanosciences Holdings, Inc. (BFNH) a corporation duly organized under the

RSDL ENTERPRISES CONSULTING AGREEMENT

Exhibit 10.3 RSDL ENTERPRISES CONSULTING AGREEMENT BioForce NanoSciences Holdings, Inc. desires to have services provided by Aldo Dalla-Vecchia of RSDL Enterprises. Therefore, the parties agree as follows: 1. DESCRIPTION OF SERVICES. Beginning on March 16, 2020, Aldo Dalla-Vecchia will provide the following services (collectively, the "Services"): General Consulting for Management 2. PERFORMANCE O

Employment Agreement - Kaiser (1)

Exhibit 10.2 Director/ Chief Financial Officer/ Secretary Compensation AGREEMENT This Director, Chief Financial Officer/ Secretary (DCFOS) Compensation Agreement (this “Agreement”) is made as of the 31st day of March 2020 by and among Bioforce Nanosciences Holdings, Inc. (BFNH) a Delaware Corporation, having its principal place of business at 2020 General Booth Blvd., Unit 230 Virginia Beach, VA 2

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2020 BIOFORCE NANOSCIENCS HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (C

BFNH / BioForce Nanosciences Holdings, Inc. 10-K/A - Annual Report - AMENDED YEAR- END REPORT- DEC.31, 2019

10-K/A 1 bfnh03092020form10kadec2019.htm AMENDED YEAR- END REPORT- DEC.31, 2019 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1 to Form 10-K) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN

BFNH / BioForce Nanosciences Holdings, Inc. 10-K - Annual Report - YEAR - END REPORT-DEC.31, 2019

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-510

BFNH / BioForce Nanosciences Holdings, Inc. DEFR14C - - REVISED DEFINITIVE INFORMATION STATEMENT

DEFR14C 1 bfnh12302019defr14c.htm REVISED DEFINITIVE INFORMATION STATEMENT SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION (Revised No. 1) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement (Revised No.1) [ ] C

Amended Articles of Incorporation (1)

EX-3.1 2 ex31.htm ARTICLES OF AMENDMENT TO THE ARTICLES OF INCORPORATION Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be

PLAN OF RECAPITALIZATION

Converted by EDGARwiz Exhibit 99.1 PLAN OF RECAPITALIZATION On November 22, 2019 the Board of Directors of BioForce Nanosciences Holdings, Inc. (the “Company”) adopted a resolution declaring it to be in the best interest of the Company and its Shareholders to effectuate a 5-to-1 reverse split of the Company’s Common Stock. In furtherance of that Plan, the Board of Directors hereby submits to the S

BFNH / BioForce Nanosciences Holdings, Inc. DEFR14C - - REVISED DEFINITIVE INFORMATION STATEMENT NO. 2 INCLUDES EXHIBITS

DEFR14C 1 bfnh12312019defr14c2.htm REVISED DEFINITIVE INFORMATION STATEMENT NO. 2 INCLUDES EXHIBITS SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION (Revised No. 2) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information State

BFNH / BioForce Nanosciences Holdings, Inc. DEF 14C - - DEFINITIVE INFORMATION STATEMENT

SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [ ] Preliminary Information Statement [X] Definitive Information Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) BIOFORCE NANOSCIENCES HOLDINGS, INC.

AMENDED AND RESTATED ARTICLES OF INCORPORATION BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I

Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be to engage in any lawful activity, to do all and everything necessary, su

PLAN OF RECAPITALIZATION

Converted by EDGARwiz Exhibit 99.1 PLAN OF RECAPITALIZATION On November 22, 2019 the Board of Directors of BioForce Nanosciences Holdings, Inc. (the “Company”) adopted a resolution declaring it to be in the best interest of the Company and its Shareholders to effectuate a 5-to-1 reverse split of the Company’s Common Stock. In furtherance of that Plan, the Board of Directors hereby submits to the S

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP - -

JONES & HALEY, P.C. ATTORNEYS AT LAW 750 HAMMOND DRIVE, SUITE 100, BUILDING 12 ATLANTA, GEORGIA 30328 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 December 27, 2019 United States Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Chris Edwards Re: BioForce

BFNH / BioForce Nanosciences Holdings, Inc. PRER14C - - REVISED PRELIMINARY INFO. STATEMENT

SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION (Revised No.

PLAN OF RECAPITALIZATION

EX-99.1 3 ex991.htm PLAN OF RECAPITALIZATION Exhibit 99.1 PLAN OF RECAPITALIZATION On November 22, 2019 the Board of Directors of BioForce Nanosciences Holdings, Inc. (the “Company”) adopted a resolution declaring it to be in the best interest of the Company and its Shareholders to effectuate a 5-to-1 reverse split of the Company’s Common Stock. In furtherance of that Plan, the Board of Directors

AMENDED AND RESTATED ARTICLES OF INCORPORATION BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I

Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be to engage in any lawful activity, to do all and everything necessary, su

BFNH / BioForce Nanosciences Holdings, Inc. PRE 14C - - PRELIMINARY INFORMATION STATEMENT

PRE 14C 1 bfnh12132019pre14c.htm PRELIMINARY INFORMATION STATEMENT SCHEDULE 14 C (Rule 14c-101) INFORMATION REQUIRED IN INFORMATION STATEMENT SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: [X] Preliminary Information Statement [ ] Definitive Information Statement [ ] Confidential, For Use of the Commission

BFNH / BioForce Nanosciences Holdings, Inc. 10-Q - Quarterly Report - QTR. ENDING SEPT. 30, 2019

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as spec

BFNH / BioForce Nanosciences Holdings, Inc. 10-Q - Quarterly Report - QTR. ENDING JUNE 30, 2019

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified

BFNH / BioForce Nanosciences Holdings, Inc. 10-Q Quarterly Report QTR. MARCH 31, 2019

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2019 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie

BFNH / BioForce Nanosciences Holdings, Inc. YEAR END REPORT- DECEMBER 31, 2018 (Annual Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-510

BFNH / BioForce Nanosciences Holdings, Inc. QTR. REPORT-SEPT. 30, 2018 (Quarterly Report)

10-Q 1 bfnh10182018form10qsept.htm QTR. REPORT-SEPT. 30, 2018 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE

BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 6 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb

BFNH / BioForce Nanosciences Holdings, Inc. QTR. REPORT_JUNE 30, 2018 (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specified

BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 5 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 4 5 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Nu

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

JONES & HALEY, P.C. ATTORNEYS AT LAW 750 HAMMOND DRIVE, SUITE 100, BUILDING 12 ATLANTA, GEORGIA 30328 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 June 28, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Tom Jones Re: BioFo

BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 4 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

JONES & HALEY, P.C. ATTORNEYS AT LAW 750 HAMMOND DRIVE, SUITE 100, BUILDING 12 ATLANTA, GEORGIA 30328 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 May 25, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: Tom Jones Re: BioFor

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

CORRESP 2 filename2.htm U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 3 4 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporat

BFNH / BioForce Nanosciences Holdings, Inc. QTR. REPORT- MARCH 31, 2018 (Quarterly Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2018 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Exact name of registrant as specifie

CONTRACT

Converted by EDGARwiz Exhibit 10.3 CONTRACT Richard Kaiser agrees to provide Director and Corporate Officer services for BioForce Nanosciences Holdings, Inc. yearly, at no cost to the Company, and he continues to provide necessary office space and executive services in aforementioned space at no cost to Company. /s/ Richard Kaiser Director/Acting CFO/Secretary /s/ Merle Ferguson President/CEO/Chai

April, 25, 2018

04/25/2018 updated U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 3 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (C

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

JONES & HALEY, P.C. ATTORNEYS AT LAW SOUTH TERRACES, SUITE 170 115 PERIMETER CENTER PLACE ATLANTA, GEORGIA 30346-1238 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 April 25, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn: To

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 2 3 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Nu

BFNH / BioForce Nanosciences Holdings, Inc. YEAR END REPORT- DECEMBER 31, 2017 (Annual Report)

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-510

BFNH / BioForce Nanosciences Holdings, Inc. NOTIFICATION OF LATE FILING

(Check One): x Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

BFNH / BioForce Nanosciences Holdings, Inc. AMENDED REGISTRATION STATEMENT

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 2 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1 2 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Nu

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

JONES & HALEY, P.C. ATTORNEYS AT LAW SOUTH TERRACES, SUITE 170 115 PERIMETER CENTER PLACE ATLANTA, GEORGIA 30346-1238 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 February 28, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn:

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificatio

BFNH / BioForce Nanosciences Holdings, Inc. CORRESP

JONES & HALEY, P.C. ATTORNEYS AT LAW SOUTH TERRACES, SUITE 170 115 PERIMETER CENTER PLACE ATLANTA, GEORGIA 30346-1238 RICHARD W. JONES www.corplaw.net Telephone 770-804-0500 Email: [email protected] Facsimile 770-804-0509 January 26, 2018 Russell Mancuso, Branch Chief Office of Electronics and Machinery United States Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn:

Chairman Director

EX-10.2 3 ex1002.htm MATERIAL CONTRACT Exhibit 10.2 Chairman Director Compensation AGREEMENT This Director Compensation Agreement (this “Agreement”) is made as of the 1st day of July, 2013 by and among BioForce Nanosciences Holdings, Inc. (BFNH), a Nevada Corporation, having its principal place of business at 2232 Virginia Beach Blvd, Virginia Beach, VA 23454 (“Company”), and Merle Ferguson, Chair

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10/A (Amendment No. 1 to FORM 10) GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Numb

Supplier Agreement (Previously filed as Exhibit 10.1 on Form 10/A)(1)

Exhibit 10.1 Supplier Agreement This Supplier Agreement (this "Agreement") is made effective as of February 5th, 2015, between Body Align, LLC, of 2296 Chamberino Dr, Virginia Beach, Virginia 23456 ("Supplier"), and BioForce Nanosciences Holdings, Inc. (a Nevada Corporation) with its office at 3419 Virginia Beach, Suite 252, Virginia Beach, Virginia 23452("Customer"). This agreement will remain in

EX-4.1

Exhibit 4.1

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10 GENERAL FORM FOR REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOFORCE NANOSCIENCES HOLDINGS, INC. (Name of Small Business Issuer in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identificatio

Certificate of Incorporation (1)

EX-3.1 2 ex31.htm ARTICLES OF INCORPORATIONS Exhibit- 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF BIOFORCE NANOSCIENCES HOLDINGS, INC. ARTICLE I Name The name of the Company is BioForce NanoSciences Holdings, Inc. ARTICLE II Business The purpose and nature of the business, objectives, or purposes to be transacted, promoted, or carried on by the Company shall be to engage in any lawful ac

Bylaws (1)

EX-3.2 3 ex32.htm BYLAWS Exhibit 3.2 BIOFORCE NANAOSCIENCES HOLDINGS, INC. AMENDED BY - LAWS ARTICLE I OFFICES Section 1. The principal office shall be in the City of Virginia Beach, Virginia. Section 2. The corporation may also have offices at such other places both within and without the State of Nevada as the board of directors may from time to time determine or the business of the corporation

BioForce Nanosciences Holdings CURRENT REPORT (Current Report/Significant Event)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2017 BIOFORCE NANOSCIENCES HOLDINGS, INC (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-51074 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

(Check One): x Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form N-SAR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

EMPLOYEE COMPENSATION AGREEMENT

EMPLOYEE COMPENSATION AGREEMENT THIS EMPLOYEE COMPENSATION AGREEMENT (the “Agreement”) is entered into this 11th day of March, 2009, by and between BioForce Nanosciences, Inc.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2009 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (

PROMISSORY NOTE

Attachment C1 PROMISSORY NOTE $92,253.82 Des Moines, Iowa February 25, 2009 FOR THE VALUE RECEIVED, BioForce Nanosciences, Inc., (the Borrower), located at 1615 Golden Aspen Drive, Suite 101, Ames, Iowa, 50010, promises to pay to the State of Iowa, Department of Economic Development (the "Department"), located at 200 East Grand Avenue, Des Moines, Iowa, 50309, the principal sum of ninety two thous

Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2009 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)

NOTICE OF DEFAULT OPPORTUNITY TO CURE

NOTICE OF DEFAULT AND OPPORTUNITY TO CURE January 26, 2009 Greg Brown BioForce Nanosciences, Inc.

EX-99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2009 BioForce Nanosci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2009 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)

CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT

EX-10.1 4 ex101.htm MATERIAL CONTRACT CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT Dated as of November 17, 2008 among BIOFORCE NANOSCIENCES HOLDINGS, INC. and THE PURCHASERS LISTED ON EXHIBIT A CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT This CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT (the “Agreement”) is dated as of November 17

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation

BIOFORCE NANOSCIENCES HOLDINGS, INC. CONVERTIBLE SECURED PROMISSORY NOTE

EXHIBIT 4.1 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY MAY REFUSE TO AUTHORIZE ANY TRANSFER OF THE S

WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOFORCE NANOSCIENCES HOLDINGS, INC. Expires November 17, 2013 Date of Issuance: November 17, 2008 Number of Shares: 62,5000

Converted by EDGARwiz Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY MAY REFUSE TO AUTHORIZ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDI

Amendment Number 1 Employment Agreement

Exhibit 4.2 Amendment Number 1 to Employment Agreement This Amendment Number 1 (the ?Amendment?) dated November 10, 2008, amends the Employment Agreement (the ?Agreement?) between BioForce Nanosciences Holdings, Inc. (the ?Company?) and Gregory D. Brown (the ?Employee?) In consideration of the mutual agreements set forth below and other good and valuable consideration, the receipt and adequacy of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 bfnh1111088k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State o

Amendment Number 3 Employment Agreement

Exhibit 4.1 Amendment Number 3 to Employment Agreement This Amendment Number 3 (the ?Amendment?) dated November 6, 2008, amends the Employment Agreement (the ?Agreement?) between BioForce Nanosciences Holdings, Inc. (the ?Company?) and Kerry Frey (the ?Employee?) In consideration of the mutual agreements set forth below and other good and valuable consideration, the receipt and adequacy of which a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1 to Form 10-Q) (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment No. 1 to Form 10-QSB)

BFNH 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB/A (Amendment No. 1 to Form 10-QSB) (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A (Amendment No. 1 to Form 10-KSB) (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00

- -1-

August 26, 2008 Mr. Gary Todd United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Dear Mr. Todd: I am responding to your letter, dated July 22, 2008, with comments on our Form 10-KSB for the year ended December 31, 2007, and Form 10-QSB for the quarter ended March 31, 2008. Following are our responses to your comments. Form 10-KSB 1. Please see the enclosed m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

BFNH 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2008 BioForce Nanoscie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation)

SHAREHOLDER AGREEMENT Relating to ASPERA CORP. (a Delaware corporation)

Exhibit 10.2 SHAREHOLDER AGREEMENT Relating to ASPERA CORP. (a Delaware corporation) This Shareholder Agreement (Agreement) is entered into by and among the named Shareholders set forth on Exhibit A, attached hereto and made a part hereof, BioForce Nanosciences, Inc. (BioForce), and Aspera Corp. (Aspera), effective the 11th day of August, 2008 (Effective Date) with respect to the transfer of certa

EMPLOYMENT AGREEMENT

Exhibit 10.3 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (this “Agreement”) effective as of September 1, 2008 between BioForce Nanosciences Holdings, Inc (the “Company”), a Nevada corporation, and Eric R. Henderson (the “Employee”), a resident of the State of Iowa. WHEREAS, the Company wishes to employ the Employee to render services for the Company on the terms and conditions set forth in this Agre

BIOFORCE NANOSCIENCES ENTERS INTO LICENSING AGREEMENT WITH ASPERA CORP. Operating Costs to be Reduced by 20% Annually; BioForce Receives Equity Interest in Aspera; Potential for Licensing Income to BioForce

Exhibit 99.1 BIOFORCE NANOSCIENCES ENTERS INTO LICENSING AGREEMENT WITH ASPERA CORP. Operating Costs to be Reduced by 20% Annually; BioForce Receives Equity Interest in Aspera; Potential for Licensing Income to BioForce AMES, IA, August 12, 2008 - BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micr

License Agreement

Exhibit 10.1 License Agreement This License Agreement ("Agreement") is entered into as of the 11th day of August, 2008 by and between BioForce Nanosciences, Inc. ("BIOFORCE"), a Delaware corporation with its principal place of business located at 1615 Golden Aspen Dr., Ste 101, Ames, IA 50010-8098 USA, and Aspera Corp. (?ASPERA?), a Delaware corporation with its principal place of business located

CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT

EX-10.1 4 ex101.htm MATERIAL CONTRACT EXHIBIT 10.1 CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT Dated as of July 21, 2008 among BIOFORCE NANOSCIENCES HOLDINGS, INC. and THE PURCHASERS LISTED ON EXHIBIT A CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT This CONVERTIBLE SECURED PROMISSORY NOTE AND WARRANT PURCHASE AGREEMENT (the “Agreement”) is dated as of Ju

BIOFORCE NANOSCIENCES HOLDINGS, INC. CONVERTIBLE SECURED PROMISSORY NOTE

EX-4.1 2 ex41.htm RIGHTS OF SECURITY HOLDER EXHIBIT 4.1 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY M

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2008 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction of incorporation) (C

BIOFORCE NANOSCIENCES COMPLETES SECOND PHASE OF FINANCING

EXHIBIT 99.1 BIOFORCE NANOSCIENCES COMPLETES SECOND PHASE OF FINANCING AMES, IA, July 23, 2008 - BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micro and nano scales, today announced the completion of a $300,000 convertible debt financing. This is the second phase of the Company’s 2008 financing st

WARRANT TO PURCHASE SHARES OF COMMON STOCK BIOFORCE NANOSCIENCES HOLDINGS, INC. Expires July 21, 2013

EXHIBIT 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR COMPLIANCE WITH AN AVAILABLE EXEMPTION FROM REGISTRATION. THE COMPANY MAY REFUSE TO AUTHORIZE ANY TRANSFER OF THE

AMENDMENT NUMBER 2 to the October 14, 2002 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT

AMENDMENT NUMBER 2 to the October 14, 2002 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This Amendment Number 2 to the October 14, 2002 Amended and Restated Registration Rights Agreement ( “Amendment Number 2”), made effective as of May 5, 2008, is by and between the Holders and BioForce Nanosciences Holdings, Inc.

MASTER EQUIPMENT LEASE AGREEMENT LESSOR: RELATIONAL, LLC ADDRESS: 3701 Algonquin Road, Suite 600 Rolling Meadows, IL 60008 Tel: (847) 818-1700 LESSEE: BIOFORCE NANOSCIENCES, INC., a Delaware corporation DATE: March 28, 2008 ADDRESS: 1615 Golden Aspen

EX-10.1 2 e603825ex10-1.htm MASTER EQUIPMENT LEASE AGREEMENT LESSOR: RELATIONAL, LLC ADDRESS: 3701 Algonquin Road, Suite 600 Rolling Meadows, IL 60008 Tel: (847) 818-1700 LESSEE: BIOFORCE NANOSCIENCES, INC., a Delaware corporation DATE: March 28, 2008 ADDRESS: 1615 Golden Aspen Drive, Suite 101 Ames, IA 50010 Lessee agrees to lease from Lessor the Equipment described in each related Schedule which

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDINGS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

AMENDMENT NUMBER 2 EMPLOYMENT AGREEMENT

AMENDMENT NUMBER 2 to EMPLOYMENT AGREEMENT This AMENDMENT NUMBER 2 (?Amendment?) dated January 21, 2008 amends the Employment Agreement (?Agreement?) between BioForce Nanosciences Holdings, Inc.

SILVER RIVER VENTURES, INC. * * * * * BY - LAWS * * * * * ARTICLE I

SILVER RIVER VENTURES, INC. * * * * * BY - - LAWS * * * * * ARTICLE I OFFICES Section 1. The principal office shall be in the City of Clark Fork, Idaho. Section 2. The corporation may also have offices at such other places both within and without the State of Nevada as the board of directors may from time to time determine or the business of the corporation may require. ARTICLE II MEETINGS OF STOC

ATTACHMENT B1 PROMISSORY NOTE BioForce Nanosciences

ATTACHMENT B1 PROMISSORY NOTE BioForce Nanosciences IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT PIAP PROGRAM PROMISSORY NOTE Loan Number: 03-PIAP-04 Des Moines, Iowa $69,999 November 5, 2007 FOR VALUE RECEIVED, the undersigned (hereafter called the ?Maker?) promises to pay to the order of the State of Iowa, Department of Economic Development (hereafter called the ?Payee?) at its office at 200 East Gra

USER SERVICE AGREEMENT

USER SERVICE AGREEMENT This Agreement is made this 17th day of March, 2008 by and between CJM Financial, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIENCES HOLDI

AMENDMENT NUMBER 2 EMPLOYMENT AGREEMENT

AMENDMENT NUMBER 2 to EMPLOYMENT AGREEMENT This AMENDMENT NUMBER 2 (“Amendment”) dated January 21, 2008 amends the Employment Agreement (“Agreement”) between BioForce Nanosciences Holdings, Inc.

EX-99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-QSB (Mark One) ý QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51074 BIOFORCE NANOSCIEN

EX-10.2

EX-10.1

AMENDMENT PROGRAM: PIAP CONTRACT NUMBER: 03-PIAP-04 AMENDMENT NUMBER: 1 EFFECTIVE DATE: October 30, 2007

EX-10.3 8 e602834ex10-3.htm Page of 1 Amendment No. 1 Contract No. 03-PIAP-04 AMENDMENT PROGRAM: PIAP CONTRACT NUMBER: 03-PIAP-04 AMENDMENT NUMBER: 1 EFFECTIVE DATE: October 30, 2007 THIS AMENDMENT is made by and between the IOWA DEPARTMENT OF ECONOMIC DEVELOPMENT, (hereafter "Department"), 200 East Grand Avenue, Des Moines, Iowa 50309, an agency of the State of Iowa and BioForce Nanosciences, Inc

From: Debra Happe [[email protected]]

EX-99.1 [e-mail] From: Debra Happe [[email protected]] Sent: Monday, June 18, 2007 2:06 PM To: Debra Happe Subject: RedChip Initiates Research On BioForce Nanosciences Holdings, Inc. RedChip Visibility, a division of RedChip Companies, Inc. announced on June 12th that it has initiated research on BioForce Nanosciences Holdings, Inc. (OTC BB:BFNH.OB - News) Nancy Hull, MBA, RedChip Research A

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 18, 2007 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125 (State or other jurisdiction (Commission (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

BioForce Nanosciences Holdings, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 13, 2007 BioForce Nanosciences Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 000-51074 74-3078125

BIOFORCE NANOSCIENCES ANNOUNCES EXECUTIVE APPOINTMENTS

[BioForce Nanosciences letterhead] FOR RELEASE: June 15, 2007, 12:02 p.m. EDT Contact: Investor Relations RedChip Companies Inc. Robert Rehse 1-800-REDCHIP (733-2447) ext 111 Company Contact: Deb Happe, Director of Communications 515-233-8333, Ext. 123 [email protected] BIOFORCE NANOSCIENCES ANNOUNCES EXECUTIVE APPOINTMENTS AMES, IA?BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH) announce

EX-99.1

EX-99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2007 BIOFORCE NANOSCIENCES HOLDINGS, INC.